Upregulation of integrin expression on monocytes in multiple sclerosis patients treated with natalizumab
Abstract Natalizumab is a humanized monoclonal antibody against the α4 subunit of VLA-4 integrin that is used to treat conditions such as multiple sclerosis (MS). Although its effects on lymphocytes have been widely described, little is known about its effects on monocytes. Here we described the eff...
Gespeichert in:
| Veröffentlicht in: | Journal of neuroimmunology 2015-10, Vol.287, p.76-79 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 79 |
|---|---|
| container_issue | |
| container_start_page | 76 |
| container_title | Journal of neuroimmunology |
| container_volume | 287 |
| creator | Dallari, Simone Franciotta, Diego Carluccio, Silvia Signorini, Lucia Gastaldi, Matteo Colombo, Elena Bergamaschi, Roberto Elia, Francesca Villani, Sonia Ferrante, Pasquale Delbue, Serena |
| description | Abstract Natalizumab is a humanized monoclonal antibody against the α4 subunit of VLA-4 integrin that is used to treat conditions such as multiple sclerosis (MS). Although its effects on lymphocytes have been widely described, little is known about its effects on monocytes. Here we described the effects of natalizumab treatment on peripheral blood monocytes from a small cohort of MS patients in terms of relative frequencies and surface integrin (CD49d and CD18) expression. We showed that natalizumab treatment altered the surface integrin expression on monocyte subsets in the peripheral compartment, suggesting a role for them as mediators of natalizumab effects. |
| doi_str_mv | 10.1016/j.jneuroim.2015.08.010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1727680855</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165572815300254</els_id><sourcerecordid>1720452097</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-8204952059e15e578a62e216dec2fdb96357dedfe066dc7843e3229f197876f3</originalsourceid><addsrcrecordid>eNqNkk2P1SAUhonRONfRvzBh6aYVaPnoxmgmfiWTuHBcEy49naFSqEDV66-X651x4UZXJPCc9xzO-yJ0QUlLCRUv5nYOsKXolpYRyluiWkLJA7SjSrJG9Yw-RLsK8oZLps7Qk5xnUsGuHx6jMyb6bhgE36Hbz2uCm82b4mLAccIuFLhJLmD4UV9y_n0d8BJDtIcCuQJ42XxxqwecrYcUs8t4rQIQSsYlgSkw4u-u3OJgivHu57aY_VP0aDI-w7O78xxdv31zffm-ufr47sPl66vG9lyURjHSD5wRPgDlwKUyggGjYgTLpnE_iI7LEcYJiBCjlarvoGNsmOgglRRTd46en2TXFL9ukIteXLbgvQkQt6ypZFIoojj_H5T0dZRBVlScUFt_mxNMek1uMemgKdFHP_Ss7_3QRz80Ubr6UQsv7nps-wXGP2X3BlTg1QmAupNvDpLOti7SwugS2KLH6P7d4-VfEta74KzxX-AAeY5bCnXjmurMNNGfjqk4hqKGgRDG--4X42q2RQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1720452097</pqid></control><display><type>article</type><title>Upregulation of integrin expression on monocytes in multiple sclerosis patients treated with natalizumab</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Dallari, Simone ; Franciotta, Diego ; Carluccio, Silvia ; Signorini, Lucia ; Gastaldi, Matteo ; Colombo, Elena ; Bergamaschi, Roberto ; Elia, Francesca ; Villani, Sonia ; Ferrante, Pasquale ; Delbue, Serena</creator><creatorcontrib>Dallari, Simone ; Franciotta, Diego ; Carluccio, Silvia ; Signorini, Lucia ; Gastaldi, Matteo ; Colombo, Elena ; Bergamaschi, Roberto ; Elia, Francesca ; Villani, Sonia ; Ferrante, Pasquale ; Delbue, Serena</creatorcontrib><description>Abstract Natalizumab is a humanized monoclonal antibody against the α4 subunit of VLA-4 integrin that is used to treat conditions such as multiple sclerosis (MS). Although its effects on lymphocytes have been widely described, little is known about its effects on monocytes. Here we described the effects of natalizumab treatment on peripheral blood monocytes from a small cohort of MS patients in terms of relative frequencies and surface integrin (CD49d and CD18) expression. We showed that natalizumab treatment altered the surface integrin expression on monocyte subsets in the peripheral compartment, suggesting a role for them as mediators of natalizumab effects.</description><identifier>ISSN: 0165-5728</identifier><identifier>EISSN: 1872-8421</identifier><identifier>DOI: 10.1016/j.jneuroim.2015.08.010</identifier><identifier>PMID: 26439965</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adult ; Allergy and Immunology ; Antigens, CD - metabolism ; Female ; Follow-Up Studies ; Humans ; Immunologic Factors - pharmacology ; Immunologic Factors - therapeutic use ; Integrins - metabolism ; Male ; Middle Aged ; Monocytes ; Monocytes - classification ; Monocytes - drug effects ; Multiple sclerosis ; Multiple Sclerosis - drug therapy ; Multiple Sclerosis - pathology ; Natalizumab ; Natalizumab - pharmacology ; Natalizumab - therapeutic use ; Neurology ; Statistics, Nonparametric ; Up-Regulation - drug effects</subject><ispartof>Journal of neuroimmunology, 2015-10, Vol.287, p.76-79</ispartof><rights>Elsevier B.V.</rights><rights>2015 Elsevier B.V.</rights><rights>Copyright © 2015 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-8204952059e15e578a62e216dec2fdb96357dedfe066dc7843e3229f197876f3</citedby><cites>FETCH-LOGICAL-c456t-8204952059e15e578a62e216dec2fdb96357dedfe066dc7843e3229f197876f3</cites><orcidid>0000-0002-3199-9369</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jneuroim.2015.08.010$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26439965$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dallari, Simone</creatorcontrib><creatorcontrib>Franciotta, Diego</creatorcontrib><creatorcontrib>Carluccio, Silvia</creatorcontrib><creatorcontrib>Signorini, Lucia</creatorcontrib><creatorcontrib>Gastaldi, Matteo</creatorcontrib><creatorcontrib>Colombo, Elena</creatorcontrib><creatorcontrib>Bergamaschi, Roberto</creatorcontrib><creatorcontrib>Elia, Francesca</creatorcontrib><creatorcontrib>Villani, Sonia</creatorcontrib><creatorcontrib>Ferrante, Pasquale</creatorcontrib><creatorcontrib>Delbue, Serena</creatorcontrib><title>Upregulation of integrin expression on monocytes in multiple sclerosis patients treated with natalizumab</title><title>Journal of neuroimmunology</title><addtitle>J Neuroimmunol</addtitle><description>Abstract Natalizumab is a humanized monoclonal antibody against the α4 subunit of VLA-4 integrin that is used to treat conditions such as multiple sclerosis (MS). Although its effects on lymphocytes have been widely described, little is known about its effects on monocytes. Here we described the effects of natalizumab treatment on peripheral blood monocytes from a small cohort of MS patients in terms of relative frequencies and surface integrin (CD49d and CD18) expression. We showed that natalizumab treatment altered the surface integrin expression on monocyte subsets in the peripheral compartment, suggesting a role for them as mediators of natalizumab effects.</description><subject>Adult</subject><subject>Allergy and Immunology</subject><subject>Antigens, CD - metabolism</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Immunologic Factors - pharmacology</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Integrins - metabolism</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monocytes</subject><subject>Monocytes - classification</subject><subject>Monocytes - drug effects</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis - drug therapy</subject><subject>Multiple Sclerosis - pathology</subject><subject>Natalizumab</subject><subject>Natalizumab - pharmacology</subject><subject>Natalizumab - therapeutic use</subject><subject>Neurology</subject><subject>Statistics, Nonparametric</subject><subject>Up-Regulation - drug effects</subject><issn>0165-5728</issn><issn>1872-8421</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkk2P1SAUhonRONfRvzBh6aYVaPnoxmgmfiWTuHBcEy49naFSqEDV66-X651x4UZXJPCc9xzO-yJ0QUlLCRUv5nYOsKXolpYRyluiWkLJA7SjSrJG9Yw-RLsK8oZLps7Qk5xnUsGuHx6jMyb6bhgE36Hbz2uCm82b4mLAccIuFLhJLmD4UV9y_n0d8BJDtIcCuQJ42XxxqwecrYcUs8t4rQIQSsYlgSkw4u-u3OJgivHu57aY_VP0aDI-w7O78xxdv31zffm-ufr47sPl66vG9lyURjHSD5wRPgDlwKUyggGjYgTLpnE_iI7LEcYJiBCjlarvoGNsmOgglRRTd46en2TXFL9ukIteXLbgvQkQt6ypZFIoojj_H5T0dZRBVlScUFt_mxNMek1uMemgKdFHP_Ss7_3QRz80Ubr6UQsv7nps-wXGP2X3BlTg1QmAupNvDpLOti7SwugS2KLH6P7d4-VfEta74KzxX-AAeY5bCnXjmurMNNGfjqk4hqKGgRDG--4X42q2RQ</recordid><startdate>20151015</startdate><enddate>20151015</enddate><creator>Dallari, Simone</creator><creator>Franciotta, Diego</creator><creator>Carluccio, Silvia</creator><creator>Signorini, Lucia</creator><creator>Gastaldi, Matteo</creator><creator>Colombo, Elena</creator><creator>Bergamaschi, Roberto</creator><creator>Elia, Francesca</creator><creator>Villani, Sonia</creator><creator>Ferrante, Pasquale</creator><creator>Delbue, Serena</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><orcidid>https://orcid.org/0000-0002-3199-9369</orcidid></search><sort><creationdate>20151015</creationdate><title>Upregulation of integrin expression on monocytes in multiple sclerosis patients treated with natalizumab</title><author>Dallari, Simone ; Franciotta, Diego ; Carluccio, Silvia ; Signorini, Lucia ; Gastaldi, Matteo ; Colombo, Elena ; Bergamaschi, Roberto ; Elia, Francesca ; Villani, Sonia ; Ferrante, Pasquale ; Delbue, Serena</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-8204952059e15e578a62e216dec2fdb96357dedfe066dc7843e3229f197876f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Allergy and Immunology</topic><topic>Antigens, CD - metabolism</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Immunologic Factors - pharmacology</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Integrins - metabolism</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monocytes</topic><topic>Monocytes - classification</topic><topic>Monocytes - drug effects</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis - drug therapy</topic><topic>Multiple Sclerosis - pathology</topic><topic>Natalizumab</topic><topic>Natalizumab - pharmacology</topic><topic>Natalizumab - therapeutic use</topic><topic>Neurology</topic><topic>Statistics, Nonparametric</topic><topic>Up-Regulation - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dallari, Simone</creatorcontrib><creatorcontrib>Franciotta, Diego</creatorcontrib><creatorcontrib>Carluccio, Silvia</creatorcontrib><creatorcontrib>Signorini, Lucia</creatorcontrib><creatorcontrib>Gastaldi, Matteo</creatorcontrib><creatorcontrib>Colombo, Elena</creatorcontrib><creatorcontrib>Bergamaschi, Roberto</creatorcontrib><creatorcontrib>Elia, Francesca</creatorcontrib><creatorcontrib>Villani, Sonia</creatorcontrib><creatorcontrib>Ferrante, Pasquale</creatorcontrib><creatorcontrib>Delbue, Serena</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal of neuroimmunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dallari, Simone</au><au>Franciotta, Diego</au><au>Carluccio, Silvia</au><au>Signorini, Lucia</au><au>Gastaldi, Matteo</au><au>Colombo, Elena</au><au>Bergamaschi, Roberto</au><au>Elia, Francesca</au><au>Villani, Sonia</au><au>Ferrante, Pasquale</au><au>Delbue, Serena</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Upregulation of integrin expression on monocytes in multiple sclerosis patients treated with natalizumab</atitle><jtitle>Journal of neuroimmunology</jtitle><addtitle>J Neuroimmunol</addtitle><date>2015-10-15</date><risdate>2015</risdate><volume>287</volume><spage>76</spage><epage>79</epage><pages>76-79</pages><issn>0165-5728</issn><eissn>1872-8421</eissn><abstract>Abstract Natalizumab is a humanized monoclonal antibody against the α4 subunit of VLA-4 integrin that is used to treat conditions such as multiple sclerosis (MS). Although its effects on lymphocytes have been widely described, little is known about its effects on monocytes. Here we described the effects of natalizumab treatment on peripheral blood monocytes from a small cohort of MS patients in terms of relative frequencies and surface integrin (CD49d and CD18) expression. We showed that natalizumab treatment altered the surface integrin expression on monocyte subsets in the peripheral compartment, suggesting a role for them as mediators of natalizumab effects.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>26439965</pmid><doi>10.1016/j.jneuroim.2015.08.010</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-3199-9369</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0165-5728 |
| ispartof | Journal of neuroimmunology, 2015-10, Vol.287, p.76-79 |
| issn | 0165-5728 1872-8421 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1727680855 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adult Allergy and Immunology Antigens, CD - metabolism Female Follow-Up Studies Humans Immunologic Factors - pharmacology Immunologic Factors - therapeutic use Integrins - metabolism Male Middle Aged Monocytes Monocytes - classification Monocytes - drug effects Multiple sclerosis Multiple Sclerosis - drug therapy Multiple Sclerosis - pathology Natalizumab Natalizumab - pharmacology Natalizumab - therapeutic use Neurology Statistics, Nonparametric Up-Regulation - drug effects |
| title | Upregulation of integrin expression on monocytes in multiple sclerosis patients treated with natalizumab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T10%3A13%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Upregulation%20of%20integrin%20expression%20on%20monocytes%20in%20multiple%20sclerosis%20patients%20treated%20with%20natalizumab&rft.jtitle=Journal%20of%20neuroimmunology&rft.au=Dallari,%20Simone&rft.date=2015-10-15&rft.volume=287&rft.spage=76&rft.epage=79&rft.pages=76-79&rft.issn=0165-5728&rft.eissn=1872-8421&rft_id=info:doi/10.1016/j.jneuroim.2015.08.010&rft_dat=%3Cproquest_cross%3E1720452097%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1720452097&rft_id=info:pmid/26439965&rft_els_id=S0165572815300254&rfr_iscdi=true |